Marker Therapeutics (NASDAQ:MRKR) Now Covered by Canaccord Genuity Group

Equities research analysts at Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a note issued to investors on Wednesday, Marketbeat reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 396.89% from the stock’s current price.

Separately, Brookline Capital Management raised Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th.

Marker Therapeutics Stock Down 12.5 %

Shares of NASDAQ MRKR opened at $1.61 on Wednesday. Marker Therapeutics has a 1-year low of $1.35 and a 1-year high of $5.99. The company has a 50-day moving average of $2.19 and a two-hundred day moving average of $2.98.

Insider Activity at Marker Therapeutics

In other news, Director Steve Elms acquired 11,085 shares of the firm’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average price of $3.20 per share, with a total value of $35,472.00. Following the transaction, the director now directly owns 325,370 shares in the company, valued at approximately $1,041,184. The trade was a 3.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Enterprise Associates 16 New bought 554,250 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the completion of the purchase, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Marker Therapeutics

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in Marker Therapeutics during the fourth quarter worth about $50,000. Invst LLC acquired a new position in Marker Therapeutics in the 3rd quarter valued at approximately $56,000. Northern Trust Corp lifted its stake in shares of Marker Therapeutics by 66.9% in the fourth quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after acquiring an additional 21,703 shares during the period. LPL Financial LLC acquired a new position in Marker Therapeutics in the fourth quarter valued at $248,000. Finally, Aisling Capital Management LP lifted its stake in Marker Therapeutics by 3.5% in the fourth quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after buying an additional 11,084 shares during the period. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.